The role of angiotensin-converting enzyme 2 in COVID-19 induced lung injury

Main Article Content

Sara Torabi
Farbod Bahreini
Nima Rezaei


Angiotensin-converting enzyme 2, COVID-19, Lung injury


The novel coronavirus disease (COVID-19) has affected people around the world both physically and psychologically. As result, developing coronavirus-specific vaccine and/or therapeutics is now a top priority for public health agencies. Since our findings about COVID-19 are relatively new, the current knowledge about the molecular mechanism involved in pathogenicity and virulence of the novel coronavirus is not advanced. Understanding angiotensin-converting enzyme 2 (ACE2), the receptor for the coronavirus, is significantly important. To better illustrate the role of ACE2 in the severity of COVID-19 and the impact of currently used drugs on this receptor, this paper briefly reviews newly published articles in this regard.


Download data is not yet available.
Abstract 446 | PDF Downloads 199


1. CHENG H, WANG Y, WANG GQ. Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19. J Med Virol 2020
2. CHENG P, ZHU H, WITTELES RM, et al., Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Curr Cardiol Rep 2020; 22(5): 34
3. DEVAUX CA, ROLAIN J-M, COLSON P, RAOULT D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020: 105938
4. GOLSHANI M, SAGHAZADEH A, REZAEI N. SARS-CoV-2–a tough opponent for the immune system. Arch Med Res 2020
5. GUPTA R, MISRA A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). Diabetes Metab Syndr 2020
6. HOFFMANN M, SCHROEDER S, KLEINE-WEBER H, MÜLLER MA, DROSTEN C, PÖHLMANN S. Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. Antimicrob Agents Chemother 2020
7. KAI H, KAI M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res 2020: 1-7
8. LEUNG JM, YANG CX, TAM A, et al., ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020; 55(5)
9. LI Y, ZENG Z, CAO Y, et al., Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways. Sci Rep 2016; 6: 27911
10. LIU Y, YAN L-M, WAN L, et al., Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020
11. LOTFI M, HAMBLIN MR, REZAEI N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 2020; 508: 254-66
12. MOMTAZMANESH S, OCHS HD, UDDIN LQ, et al., All together to Fight Novel Coronavirus Disease (COVID-19) Am J Trop Med Hyg 2020
13. SAGHAZADEH A, REZAEI N. Immune-epidemiological parameters of the novel coronavirus – a perspective. Expert Rev Clin Immunol 2020
14. SAGHAZADEH A, REZAEI N. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharmacol 2020; 84(106560): 1-6
15. SKALNY AV, RINK L, AJSUVAKOVA OP, et al., Zinc and respiratory tract infections: Perspectives for COVID‑19. Int J Mol Med 2020; 46(1): 17-26
16. YAZDANPANAH F, HAMBLIN MR, REZAEI N. The immune system and COVID-19: friend or foe? Life Sci 2020
17. ZHENG Z, PENG F, XU B, et al., Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infection 2020

Most read articles by the same author(s)

1 2 > >>